4//SEC Filing
Stewart Jeffrey Ryan 4
Accession 0001415889-24-004417
CIK 0001551152other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 5:15 PM ET
Size
18.8 KB
Accession
0001415889-24-004417
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Transactions
- Award
Common Stock, $0.01 par value
2024-02-15+33,042→ 93,983 total - Award
Common Stock, $0.01 par value
2024-02-15+8,810→ 102,793 total - Award
Common Stock, $0.01 par value
2024-02-15+7,840→ 110,633 total - Award
Common Stock, $0.01 par value
2024-02-15+9,268→ 119,901 total - Award
Option (Right to Buy)
2024-02-15+39,085→ 39,085 totalExercise: $0.00From: 2025-02-15Exp: 2034-02-14→ Common Stock (39,085 underlying)
Holdings
- 1,338(indirect: By Trust)
Common Stock, $0.01 par value
Footnotes (6)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F5]The reporting person disclaims beneficial ownership of all securities held by his spouse.
- [F6]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,029 on February 15, 2025, 13,028 on February 15, 2026, and 13,028 on February 15, 2027.
Documents
Issuer
AbbVie Inc.
CIK 0001551152
Entity typeother
Related Parties
1- filerCIK 0001761675
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 5:15 PM ET
- Size
- 18.8 KB